Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Boston Scientific (BSX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) and Boston Scientific (BSX – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Contineum Therapeutics, Inc. Class A (CTNM)
In a report released today, Debanjana Chatterjee from JonesTrading maintained a Buy rating on Contineum Therapeutics, Inc. Class A, with a price target of $22.00. The company’s shares closed last Monday at $15.27.
According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Contineum Therapeutics, Inc. Class A with a $18.60 average price target.
See today’s best-performing stocks on TipRanks >>
Boston Scientific (BSX)
TD Cowen analyst Josh Jennings reiterated a Buy rating on Boston Scientific today and set a price target of $100.00. The company’s shares closed last Monday at $74.12.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $108.14, which is a 43.0% upside from current levels. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.
